Source: Business Wire (
click here to go to the source)
PITTSBURGH--(BUSINESS WIRE)--Cellumen, Inc., the Cellular Systems Biology Company (CSB™), announced today that it has spun-out its personalized medicine unit, which will be called Cernostics Pathology, Inc. The objective of this new company is to become the leading provider of digital imaging pathology and tissue-based diagnostics products and services applied to personalized medicine. Cernostics Pathology will build upon Cellumen's current collaborations, including the partnership with the Mayo Clinic and Foundation, in developing an advanced breast cancer diagnostic and theranostic test.
"As a result, we are spinning out our personalized medicine unit to better address the market demands. Cernostics Pathology will focus on digital imaging pathology and personalized medicine using Tissue Systems Biology (TSB™), which is CSB applied to tissues."
"Cellumen's successful application of Cellular Systems Biology (CSB™) to drug discovery, drug development and personalized medicine over the last three years has yielded strong interest across each of these application areas," stated D. Lansing Taylor, Ph.D., CEO of Cellumen. "As a result, we are spinning out our personalized medicine unit to better address the market demands. Cernostics Pathology will focus on digital imaging pathology and personalized medicine using Tissue Systems Biology (TSB™), which is CSB applied to tissues."
Dr. Taylor continued, "Cellumen will maintain its core business by focusing on the interface between early drug discovery and early toxicity testing. This Discovery Toxicology interface provides pharmaceutical researchers the means to screen compounds for broad-ranging toxic effects early in the drug discovery process, improving upon the unacceptable attrition in drug development due to toxicity."
Dr. Taylor will serve as the Chairman of Cernostics Pathology and Michel Nederlof, Ph.D., will join as the President and Chief Technology Officer. Dr. Nederlof was most recently the founder and President of QED Imaging, now part of Media Cybernetics, Inc. Rebecca Critchley-Thorne, Ph.D., will join the company as the Principal Scientist. Dr. Critchley-Thorne is a cancer biologist/immunologist most recently from Stanford University.
Cellumen is the leading innovator in Cellular Systems Biology (CSB™) solutions providing the most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting development costs. Cellumen's CSB solutions are driving Discovery Toxicology by addressing the full complexity of disease and safety. Leading global organizations such as the Mayo Clinic, Hamamatsu Photonics K.K., the EPA, FDA, NIH and top pharmaceutical companies partner with Cellumen. Cellumen (www.cellumen.com) is a portfolio company of Safeguard Scientifics, Inc. (NYSE: SFE), as well as Novitas Capital, the Pittsburgh Life Sciences Greenhouse and Innovation Works.
About Cernostics Pathology:
Cernostics Pathology is creating a complete digital imaging pathology platform by integrating the best available components, while building advanced informatics tools to manage, mine and classify patient tissue samples. Cellular Systems Biology applied to tissues has been named "Tissue Systems Biology" (TSB™) and involves the use of panels of fluorescence-based biomarkers that report the systems read-out of patient samples. The first diagnostic/theranostic test being developed is a breast cancer test as part of a collaboration with the Mayo Clinic and Foundation.